Skip to navigation Skip to content
  • The Cancer Letter on Facebook
  • The Cancer Letter on Twitter
  • The Cancer Letter on LinkedIn

The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Home
  • About
    • Our Readers
    • Our History
    • Our Contributors
    • Contact Us
    • Store
  • Current Issue
    • Past Issues
  • Podcast
    • The Directors
  • Events
  • Job Board
  • SUBSCRIBE
  • Login
  • SUBSCRIBE
  • Login
The Cancer Letter
Home
  • About
    • Our Readers
    • Our History
    • Our Contributors
    • Contact Us
    • Store
  • Current Issue
    • Past Issues
  • Podcast
    • The Directors
  • Events
  • Job Board
FreeIn Brief

USC researchers award $3.2M NIH grant to study age-related inflammation and cancer

August 14, 2026
Vol.52 No.32
Clinical Roundup

USC study shows how pieces of DNA that regulate gene expression drive prostate cancer

July 24, 2026
Vol.52 No.29
Clinical Roundup

Hormone produced by the thymus may reduce age-related inflammation and improve cancer outcomes, USC preclinical study finds

July 24, 2026
Vol.52 No.29
In Brief

USC and Tempus collaborate to create platform bridging patient care, clinical trials, and research

April 24, 2026
Vol.52 No.16
Clinical Roundup

Sylvester researchers discover pathway that could explain prostate cancer resistance to ADT treatment

December 12, 2025
Vol.51 No.45
Clinical Roundup

Five genes linked to aggressive prostate cancer in men of African descent, USC study identifies

November 07, 2025
Vol.51 No.41
Clinical Roundup

Next-gen CAR T cells show promise at treating solid tumors, USC study shows

October 10, 2025
Vol.51 No.37
Clinical Roundup

Steroids may make immunotherapy less effective for lung cancer patients, retrospective study finds

July 11, 2025
Vol.51 No.27
Clinical Roundup

USC team develops analytical tool to advance CAR T-cell therapy research

May 02, 2025
Vol.51 No.17
Clinical Roundup

USC study identifies innate immune system protein as potential target for CRC immunotherapy

November 15, 2024
Vol.50 No.43

Posts navigation

12Next

Trending Stories

  • Is it time to re-assess the practice and practicality of screening colonoscopy?
    Modeling data, ACS guideline support greater use of noninvasive tests to ease system strain, help save lives
  • As daraxonrasib hits the clinic, Frank McCormick says RAS is bigger than pancreatic cancer
  • From “default dead” to living the future of cancer care
    As founding CEO of GitLab, I went “founder mode” on my osteosarcoma
  • KRAS pioneer and Stephenson Prize winner Frank McCormick aims to prevent all KRAS cancers with a pill
  • Lou Weisbach tells us about his plan to raise $750 billion for the American Center for Cures
  • Brian Wolpin celebrates FDA approval of daraxonrasib in pancreatic cancer as the future of the field

ABOUT
ABOUT
About The Cancer Letter
Accessibility Statement
Our Contributors
Editorial policies
Store
SUBSCRIPTIONS
SUBSCRIPTIONS
Our readers
Pricing
News alerts
About IP login
Job board
CONTACT
CONTACT
Contact us
Submission guidelines
Advertise
Careers
SEE ALSO
Cancer History Project
The Cancer Letter
Copyright © 2026 The Cancer Letter Inc. All rights reserved.
Privacy Policy
Terms & Conditions
FOLLOW US
Instagram
Twitter
LinkedIn
Facebook
Vimeo
Scroll to top
Request Cancellation

Subscription Change

This change will be effective immediately and your card will be charged a prorated amount based on your existing subscription level.

OK Cancel

Renew today!

Your subscription has lapsed. Subscribe today to access this content.
SUBSCRIBE NOW

Subscriber content

Log in or subscribe to access The Cancer Letter.
LOGINSUBSCRIBE NOW
SEARCH DATE
SEARCH TEXT
      Cancel
      OK
      Cancel
      OK
      Delete Account
      Are you sure you want to delete your account? This will erase all of your account data from the site. To delete your account enter your password below
      No

      Never miss an issue!

      Get alerts for our award-winning coverage in your inbox.

      Login

       
      Forgot Password?

      Site license subscribers:
      Log in with your IP | Register a sponsored account